Theraclion said yesterday its academic development partner, the University of Virginia, won an FDA nod to launch a study of the combined use of echotherapy high intensity focused ultrasound and immunotherapy drug pembrolizumab for treating patients with breast cancer. The study will examine the combined treatment’s effect on fighting breast cancer tumor cells, the French […]
Theraclion touts Echopulse data from thyroid nodules studies
Theraclion (EPA:ALTHE) touted data today from 3 studies evaluating the use of Echopulse as a non-invasive treatment for benign thyroid nodules. One of the studies was the 1st direct comparison of echotherapy to surgery. The study, which was published in the International Journal of Hyperthermia, compared 43 patients who were treated with Theraclion’s Echopulse, an ultrasound-guided high-intensity focused ultrasound […]
7 medtech stories we missed this week: April 28, 2017
From FDA and Health Canada approvals to joint ventures, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Joimax Endovapor 2 Joimax announced in an April 26 press release that it has received FDA 510(k) clearance to market its Endovapor 2 Multi-Radio Frequency System. The device […]
Theraclion touts 2-year Echopulse data from breast fibroadenoma study
Theraclion (EPA:ALTHE) this week released 2-year results from a trial of its Echopulse non-invasive ultrasound system for treating breast fibroadenoma. Study results were published in the March 2017 issue of the Journal of Therapeutic Ultrasound, the French company said. The 20 patient study examined the use of the Echopulse system, an ultrasound-guided high-intensity focused ultrasound device, in reducing […]
First patients treated in pivotal trial for Theraclion’s Echopulse device
Theraclion (EPA:ALTHE) said today that the 1st patients were treated in the U.S. pivotal clinical trial evaluating the safety and efficacy of the company’s Echopulse echotherapy device as a non-invasive treatment for breast fibroadenomas. The clinical trial is slated to enroll 100 patients, the France-based company said, at 4 sites across the U.S. and 1 site […]
